



DECLARATION AND POWER OF ATTORNEY

(Case No. 91,297-O)

As below-named inventors, we hereby declare that:

Our residences, post office addresses and citizenship are as stated below next to our names.

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled:

INHIBITION OF HTLV-III BY EXOGENOUS OLIGONUCLEOTIDES

the specification of which is attached hereto.

We hereby state that we have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

We acknowledge the duty to disclose information which is material to the patentability of the claims of this application in accordance with Title 37, Code of Federal Regulations, Sections 1.56(a) and 1.56(b).

We hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application for patent or inventor's certificate listed below and under Title 35, United States Code, Section 120 of any international application listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

INTERNATIONAL APPLICATION: PCT/US89/00752 filed 24 February, 1989

The undersigned hereby appoints the following:

George B. Newitt	Reg. No. <u>16550</u>	Charles C. Kinne	Reg. No. <u>31631</u>
D. Dennis Allegretti	Reg. No. <u>17374</u>	Michael H. Shanahan	Reg. No. <u>24438</u>
Sheldon W. Witcoff	Reg. No. <u>17399</u>	Dale A. Malone	Reg. No. <u>32155</u>
Seymour Rothstein	Reg. No. <u>19369</u>	Robert H. Resis	Reg. No. <u>32168</u>
James V. Callahan	Reg. No. <u>20095</u>	Grantland G. Drutchas	Reg. No. <u>32565</u>
Jon O. Nelson	Reg. No. <u>24566</u>	James C. Gumina	Reg. No. <u>32898</u>
Charles F. Pigott	Reg. No. <u>19408</u>	Christopher J. Renk	Reg. No. <u>33761</u>
Charles G. Call	Reg. No. <u>20406</u>	David M. Frischkorn	Reg. No. <u>32833</u>
Ronald E. Larson	Reg. No. <u>24478</u>	Marc S. Cooperman	Reg. No. <u>34143</u>
Edward W. Remus	Reg. No. <u>25703</u>	Kyle K. Kappes	Reg. No. <u>34846</u>
Denis A. Berntsen	Reg. No. <u>26707</u>	Leon R. Yankwich	Reg. No. <u>30237</u>
John J. McDonnell	Reg. No. <u>26949</u>	Barbara A. Heaphy	Reg. No. <u>34619</u>
Charles W. Shifley	Reg. No. <u>28042</u>	Richard A. Clegg	Reg. No. <u>33485</u>
Daniel A. Boehnen	Reg. No. <u>28399</u>	John P. Iwanicki	Reg. No. <u>34628</u>
Jamie S. Smith	Reg. No. <u>27390</u>	A. Blair Hughes	Reg. No. <u>32901</u>
Mark T. Banner	Reg. No. <u>29888</u>	Lawrence H. Aaronson	Reg. No. <u>35818</u>
Bradley J. Hulbert	Reg. No. <u>30130</u>	Thomas A. Fairhall	Reg. No. <u>34591</u>
Paul H. Berghoff	Reg. No. <u>30243</u>	Kenneth J. Rudofski	Reg. No. <u>35997</u>
Jerry A. Riedinger	Reg. No. <u>30582</u>	Steven J. Sarussi	Reg. No. <u>32784</u>
Peter D. McDermott	Reg. No. <u>29411</u>	Michael S. Greenfield	Reg. No. <u>37142</u>

J. Pieter van Es
Thomas K. Pratt
Sanjay Prasad
Kevin E. Noonan

Reg. No. 37746
Reg. No. 37210
Reg. No. 36247
Reg. No. 35303

as our Attorneys and

Mark Chao Reg. No. 37293
Emily Miao Reg. No. 35285

as our Registered Patent Agents

the mailing address and telephone number of each of whom is BANNER & ALLEGRETTI, LTD., Ten South Wacker Drive, Chicago, Illinois 60606, and (312) 715-1000, with full power of substitution and revocation to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

The undersigned also appoints Wayne A. Keown, Reg. No. 33923 of Hybridon, Inc., One Innovation Drive, Worcester, Massachusetts 01605, with full power of substitution and revocation to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, and throughout the world with respect thereto for all corresponding applications.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first joint inventor:

1-00
John Goodchild

Inventor's signature

John Goodchild

Date

5-11-95

Residence: 11 Greybert Lane, Worcester, Massachusetts 01602

Citizenship: Citizen of the United Kingdom

Post Office Address: 11 Greybert Lane, Worcester, Massachusetts 01602

Full name of second joint inventor:

2-00
Paul C. Zamecnik

Inventor's signature

Paul Zamecnik

Date

5-17-95

Residence: 29 LeBeaux Drive, Shrewsbury, MA 01545

Citizenship: Citizen of the United States of America

Post Office Address: 29 LeBeaux Drive, Shrewsbury, MA 01545



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant or
Patentee:

John Goodchild and Paul Zamecnik

Serial or

Patent No. 08/346,270

Filed On: November 23, 1994

For: Inhibition of HTLV-III By Exogenous Oligonucleotides

(Attorney's Docket No. 91,297-O)

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 C.F.R. § 1.9(f) AND § 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am

- ☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN Worcester Foundation for Experimental Biology

ADDRESS OF CONCERN 222 Maple Avenue
Shrewsbury, MA 01545

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 C.F.R. § 121.3-18, and reproduced in 37 C.F.R. § 1.9(d), for purposes of paying reduced fees under § 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time, or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled
Inhibition of HTLV-III By Exogenous Oligonucleotides

by inventor(s) John Goodchild and Paul C. Zamecnik
described in

- ☐ the specification filed herewith
☐ Application Serial No. _____, filed _____
☐ Patent No. _____, issued _____

If the rights held by the above identified small business concern are not exclusive, each individual concern or organization having rights in the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR § 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR § 1.9(d), or a nonprofit organization under 37 CFR § 1.9(e).

FULL NAME Worcester Foundation for Experimental Biology

ADDRESS 222 Maple Avenue, Shrewsbury, MA 01545

[Individual ☒ Small Business Concern [] Nonprofit Organization

FULL NAME _____

ADDRESS _____

[] Individual [] Small Business Concern [] Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing therein, or any patent to which this verified statement is directed.

Dr. Thoru Pedersen

NAME OF PERSON SIGNING

President and Scientific Director

TITLE IN ORGANIZATION

222 Maple Avenue, Shrewsbury, MA 01545

ADDRESS OF PERSON SIGNING

Signature



May 18, 1995

Date